接受依列卡福妥-替扎卡福妥-依伐卡福妥治疗前后，成年囊性纤维化相关糖尿病患者的连续血糖监测模式
CGM patterns in adults with cystic fibrosis-related diabetes before and after elexacaftor-tezacaftor-ivacaftor therapy.
作者信息
Crow Hanna, Bengtson Charles, Shi Xiaosong, Graves Leland, Anabtawi Abeer
机构信息
University of Kansas Medical Center, Department of Internal Medicine, Division of Endocrinology, Metabolism & Clinical Pharmacology, 4000 Cambridge Blvd, Kansas City, KS 66160, USA.
University of Kansas Medical Center, Department of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, 4000 Cambridge Blvd, Kansas City, KS 66160, USA.
出版信息
J Clin Transl Endocrinol. 2022 Oct 1;30:100307. doi: 10.1016/j.jcte.2022.100307. eCollection 2022 Dec.
Abstract
Cystic fibrosis-related diabetes (CFRD) is a common complication of cystic fibrosis that is associated with worse outcomes and higher mortality rates. CF transmembrane conductance regulator gene (CFTR) modulators have shown favorable effects on lung function, pulmonary exacerbations, and nutrition status. However, data regarding effects of CFTR modulators on glycemic control among those with CFRD is lacking. In this retrospective study, CGM data was analyzed to determine effect of elexacaftortezacaftor- ivacaftor therapy (ETI), a CFTR modulator, on glucose control among patients with CFRD. No difference was seen in glucose patterns after 3- and 6- months of starting ETI.
摘要
囊性纤维化相关糖尿病（CFRD）是囊性纤维化的一种常见并发症，与更差的预后和更高的死亡率相关。囊性纤维化跨膜传导调节因子基因（CFTR）调节剂已显示出对肺功能、肺部急性加重和营养状况有良好影响。然而，关于CFTR调节剂对CFRD患者血糖控制影响的数据尚缺。在这项回顾性研究中，分析了连续血糖监测（CGM）数据，以确定CFTR调节剂依列卡福-替扎卡福-依伐卡托疗法（ETI）对CFRD患者血糖控制的影响。开始ETI治疗3个月和6个月后，血糖模式未见差异。
相似文献
1
CGM patterns in adults with cystic fibrosis-related diabetes before and after elexacaftor-tezacaftor-ivacaftor therapy.接受依列卡福妥-替扎卡福妥-依伐卡福妥治疗前后，成年囊性纤维化相关糖尿病患者的连续血糖监测模式
J Clin Transl Endocrinol. 2022 Oct 1;30:100307. doi: 10.1016/j.jcte.2022.100307. eCollection 2022 Dec.
2
The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis.依利卓（elexacaftor/tezacaftor/ivacaftor，ETI）对成年囊性纤维化患者血糖的影响。
J Cyst Fibros. 2022 Mar;21(2):258-263. doi: 10.1016/j.jcf.2021.09.001. Epub 2021 Sep 14.
3
The Effects of Elexacaftor, Tezacaftor, and Ivacaftor (ETI) on Blood Glucose in Patients With Cystic Fibrosis: A Systematic Review.依列卡福妥、替扎卡福妥和依伐卡托（ETI）对囊性纤维化患者血糖的影响：一项系统评价。
Cureus. 2023 Jul 11;15(7):e41697. doi: 10.7759/cureus.41697. eCollection 2023 Jul.
4
Effect of 18 months elexacaftor-tezacaftor-ivacaftor on body mass index and glycemic control in adults with cystic fibrosis.18 个月依伐卡托与埃乐卡福特联合治疗对囊性纤维化成人患者体重指数和血糖控制的影响。
Clin Nutr ESPEN. 2023 Dec;58:73-78. doi: 10.1016/j.clnesp.2023.08.028. Epub 2023 Aug 25.
5
Continuous glucose monitoring and advanced glycation endproducts for prediction of clinical outcomes and development of cystic fibrosis-related diabetes in adults with CF.连续血糖监测和晚期糖基化终产物预测成人 CF 相关糖尿病的临床结局和发展。
Front Endocrinol (Lausanne). 2024 Feb 6;15:1293709. doi: 10.3389/fendo.2024.1293709. eCollection 2024.
6
Clinical efficacy of elexacaftor-tezacaftor-ivacaftor in an adolescent with homozygous G85E cystic fibrosis.依列卡福妥-替扎卡福妥-依伐卡托对一名纯合子G85E囊性纤维化青少年患者的临床疗效
Respir Med Case Rep. 2022 Nov 7;40:101775. doi: 10.1016/j.rmcr.2022.101775. eCollection 2022.
7
Combined CFTR modulator therapies are linked with anabolic benefits and insulin-sparing in cystic fibrosis-related diabetes.联合CFTR调节剂疗法与囊性纤维化相关糖尿病的合成代谢益处和胰岛素节省作用相关。
J Clin Transl Endocrinol. 2023 Jun 24;33:100320. doi: 10.1016/j.jcte.2023.100320. eCollection 2023 Sep.
8
Impact of elexacaftor/tezacaftor/ivacaftor CFTR modulator therapy on rates of endoscopic sinus surgery in cystic fibrosis.依列卡福妥/替扎卡福妥/依伐卡托CFTR调节剂疗法对囊性纤维化患者鼻窦内窥镜手术发生率的影响。
Int Forum Allergy Rhinol. 2024 Nov;14(11):1692-1699. doi: 10.1002/alr.23400. Epub 2024 Jul 3.
9
Efficacy and Safety of Elexacaftor-Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review.依列卡福妥-替扎卡福妥-依伐卡托治疗囊性纤维化的疗效与安全性：一项系统评价
Children (Basel). 2023 Mar 15;10(3):554. doi: 10.3390/children10030554.
10
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.依列卡福妥联合替扎卡福妥和依伐卡托对比替扎卡福妥联合依伐卡托治疗F508del-CFTR纯合子囊性纤维化患者的疗效和安全性：一项为期24周的多中心、随机、双盲、活性对照3b期试验
Lancet Respir Med. 2022 Mar;10(3):267-277. doi: 10.1016/S2213-2600(21)00454-9. Epub 2021 Dec 20.
引用本文的文献
1
Utility of Continuous Glucose Monitors for Improved Detection of Cystic Fibrosis-Related Diabetes.连续血糖监测仪在改善囊性纤维化相关糖尿病检测方面的效用。
Pediatr Pulmonol. 2025 Aug;60(8):e71267. doi: 10.1002/ppul.71267.
2
Decreased insulin dose-adjusted hemoglobin A1c in adults with cystic fibrosis-related diabetes treated with elexacaftor-tezacaftor-ivacaftor.接受依列卡福妥-替扎卡福妥-依伐卡福妥治疗的成年囊性纤维化相关糖尿病患者中，胰岛素剂量调整后的糖化血红蛋白降低。
J Clin Transl Endocrinol. 2025 Jul 2;41:100407. doi: 10.1016/j.jcte.2025.100407. eCollection 2025 Sep.
3
Sex disparities in cystic fibrosis in the era of highly effective modulator treatment.高效调节剂治疗时代囊性纤维化中的性别差异。
BMC Pulm Med. 2025 May 2;25(1):212. doi: 10.1186/s12890-025-03621-0.
4
One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational Study.依列卡福妥/替扎卡福妥/依伐卡托治疗对胰岛素依赖型囊性纤维化相关糖尿病患者糖化血红蛋白水平和胰岛素需求的一年疗效：一项回顾性观察研究
Life (Basel). 2024 Oct 16;14(10):1309. doi: 10.3390/life14101309.
5
Development of a programmable automated cell culture system to study the lung pathophysiology of Cystic Fibrosis-related diabetes.开发一种可编程的自动化细胞培养系统，以研究囊性纤维化相关糖尿病的肺部病理生理学。
Heliyon. 2024 Sep 19;10(18):e37977. doi: 10.1016/j.heliyon.2024.e37977. eCollection 2024 Sep 30.
6
The Changing Landscape of Treatment for Cystic Fibrosis Related Diabetes.囊性纤维化相关糖尿病治疗的不断变化格局
J Clin Transl Endocrinol. 2024 Feb 28;35:100332. doi: 10.1016/j.jcte.2024.100332. eCollection 2024 Mar.
7
Efficacy and safety profile of elexacaftor-tezacaftor-ivacaftor triple therapy on cystic fibrosis: a systematic review and single arm meta-analysis.依列卡福妥-替扎卡福妥-依伐卡托三联疗法治疗囊性纤维化的疗效和安全性概况：一项系统评价和单臂荟萃分析
Front Pharmacol. 2023 Dec 14;14:1275470. doi: 10.3389/fphar.2023.1275470. eCollection 2023.
8
The Effects of Elexacaftor, Tezacaftor, and Ivacaftor (ETI) on Blood Glucose in Patients With Cystic Fibrosis: A Systematic Review.依列卡福妥、替扎卡福妥和依伐卡托（ETI）对囊性纤维化患者血糖的影响：一项系统评价。
Cureus. 2023 Jul 11;15(7):e41697. doi: 10.7759/cureus.41697. eCollection 2023 Jul.
9
Combined CFTR modulator therapies are linked with anabolic benefits and insulin-sparing in cystic fibrosis-related diabetes.联合CFTR调节剂疗法与囊性纤维化相关糖尿病的合成代谢益处和胰岛素节省作用相关。
J Clin Transl Endocrinol. 2023 Jun 24;33:100320. doi: 10.1016/j.jcte.2023.100320. eCollection 2023 Sep.
10
Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor-Ivacaftor.CFTR调节剂依列卡福-替扎卡福-依伐卡福的批准后研究。
Front Pharmacol. 2023 Mar 21;14:1158207. doi: 10.3389/fphar.2023.1158207. eCollection 2023.
本文引用的文献
1
The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis.依利卓（elexacaftor/tezacaftor/ivacaftor，ETI）对成年囊性纤维化患者血糖的影响。
J Cyst Fibros. 2022 Mar;21(2):258-263. doi: 10.1016/j.jcf.2021.09.001. Epub 2021 Sep 14.
2
Effect of CFTR modulator therapy on cystic fibrosis-related diabetes.囊性纤维化相关糖尿病的 CFTR 调节剂治疗效果。
J Diabetes Complications. 2021 Jun;35(6):107845. doi: 10.1016/j.jdiacomp.2020.107845. Epub 2021 Jan 5.
3
Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients.Lumacaftor/ivacaftor 疗法未能增加 F508del/F508del CF 患者的胰岛素分泌。
J Cyst Fibros. 2021 Mar;20(2):333-338. doi: 10.1016/j.jcf.2020.09.001. Epub 2020 Sep 8.
4
Clinical Effectiveness of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-CFTR. A Clinical Trial.鲁马卡托/依伐卡托对F508del-CFTR纯合子囊性纤维化患者的临床疗效。一项临床试验。
Ann Am Thorac Soc. 2021 Jan;18(1):75-83. doi: 10.1513/AnnalsATS.202002-144OC.
5
Effect of one-year lumacaftor-ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patients.一年卢美他南-依伐卡托治疗对囊性纤维化患者葡萄糖耐量异常的影响。
J Cyst Fibros. 2020 Sep;19(5):712-716. doi: 10.1016/j.jcf.2020.03.002. Epub 2020 Mar 19.
6
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.依伐卡托与泰比卡托和艾克卡托三联复方药物治疗携带单个 F508del 突变的囊性纤维化
N Engl J Med. 2019 Nov 7;381(19):1809-1819. doi: 10.1056/NEJMoa1908639. Epub 2019 Oct 31.
7
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.在纯合子 F508del 突变的囊性纤维化患者中，elexacaftor 加 tezacaftor 加 ivacaftor 联合治疗方案的疗效和安全性：一项双盲、随机、3 期临床试验。
Lancet. 2019 Nov 23;394(10212):1940-1948. doi: 10.1016/S0140-6736(19)32597-8. Epub 2019 Oct 31.
8
cgmanalysis: An R package for descriptive analysis of continuous glucose monitor data.cgmanalysis：一个用于连续血糖监测数据描述性分析的 R 包。
PLoS One. 2019 Oct 11;14(10):e0216851. doi: 10.1371/journal.pone.0216851. eCollection 2019.
9
Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries.依伐卡托治疗囊性纤维化患者的疾病进展：来自美国和英国国家注册中心的数据。
J Cyst Fibros. 2020 Jan;19(1):68-79. doi: 10.1016/j.jcf.2019.05.015. Epub 2019 Jun 10.
10
A Systematic Review of the Clinical Efficacy and Safety of CFTR Modulators in Cystic Fibrosis.囊性纤维化中 CFTR 调节剂的临床疗效和安全性的系统评价。
Sci Rep. 2019 May 10;9(1):7234. doi: 10.1038/s41598-019-43652-2.
Zotero 插件